share_log

Strong Week for Bausch Health Companies (NYSE:BHC) Shareholders Doesn't Alleviate Pain of Three-year Loss

Strong Week for Bausch Health Companies (NYSE:BHC) Shareholders Doesn't Alleviate Pain of Three-year Loss

bausch health公司(紐交所:BHC)的股東有了一個強勁的一週,但仍無法緩解爲期三年的虧損之痛。
Simply Wall St ·  06/22 21:01

As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of Bausch Health Companies Inc. (NYSE:BHC) investors who have held the stock for three years as it declined a whopping 77%. That'd be enough to cause even the strongest minds some disquiet. Shareholders have had an even rougher run lately, with the share price down 29% in the last 90 days.

作爲投資者,犯錯誤是不可避免的,但是你想要像瘟疫一樣避免真正的大損失。所以讓我們考慮一下,巴沙健康公司(NYSE:BHC)的股東們,他們持有該股票三年以來股價暴跌了77%,即使是最強大的頭腦也會感到煩擾。股東們近期的情況更加嚴峻,股價在過去90天中下跌了29%。

The recent uptick of 7.6% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近的7.6%上漲可能預示着未來可能會有好的跡象,因此讓我們來看看歷史基本面。

Given that Bausch Health Companies didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

鑑於巴沙健康公司在過去十二個月中沒有盈利,我們將專注於營收增長以快速了解其業務發展情況。一般來說,沒有盈利的公司每年都有望實現營收增長,而且增長速度很快。有些公司願意推遲盈利以實現更快的營收增長,但在這種情況下,人們希望有良好的營收增長來彌補缺乏收益的情況。在三年內,巴沙健康公司的營收每年增長1.7%。考慮到它在追求增長的同時在虧損,我們對此並不感到印象深刻。但是股價每年下跌21%似乎有點嚴峻!雖然我們肯定對這隻股票持謹慎態度,但在這種表現之後,這可能是一種過度反應。在考慮購買之前,請查看公司正在積累的損失情況。

Over three years, Bausch Health Companies grew revenue at 1.7% per year. Given it's losing money in pursuit of growth, we are not really impressed with that. But the share price crash at 21% per year does seem a bit harsh! While we're definitely wary of the stock, after that kind of performance, it could be an over-reaction. Before considering a purchase, take a look at the losses the company is racking up.

雖然整個市場去年增長了26%左右,但巴沙健康公司的股東們卻虧損了5.4%。即使好股票的股票價格有時也會下跌,但是在對業務基本指標產生興趣之前,我們希望看到實質性的改善。不幸的是,長期股東的損失更大,因爲在過去五年中他們損失了12%。在採取認爲股票價格將穩定的觀點之前,我們希望獲得明確的信息表明公司將會增長。我認爲,從長期來看,觀察股票價格作爲業務績效的代理是非常有趣的。但是爲了真正獲得洞察力,我們還需要考慮其他信息。爲此,您應該了解我們發現巴沙健康公司的1個警告標誌。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。

earnings-and-revenue-growth
NYSE:BHC Earnings and Revenue Growth June 22nd 2024
NYSE:BHC 財務數據及營收增長 2024年6月22日

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

資產負債表強度至關重要。查看我們關於其財務狀況如何隨時間變化的免費報告可能很值得一看。

A Different Perspective

不同的觀點

While the broader market gained around 26% in the last year, Bausch Health Companies shareholders lost 5.4%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 12% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Bausch Health Companies .

儘管整個市場去年增長了約26%,但巴沙健康公司的股東們卻虧損了5.4%。即使好股票的股票價格有時也會下跌,但在對業務基本指標產生興趣之前,我們希望看到實質性的改善。不幸的是,長期股東的損失更大,因爲在過去五年中,他們損失12%。在採取認爲股票價格將穩定的觀點之前,我們希望獲得明確的信息表明公司將會增長。我認爲,從長期來看,觀察股票價格作爲業務績效的代理是非常有趣的。但是爲了真正獲得洞察力,我們還需要考慮其他信息。爲此,您應該了解我們發現巴沙健康公司的1個警告標誌。

But note: Bausch Health Companies may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

請注意:巴沙健康公司可能不是最好的股票選擇。因此,請查看此列表,其中包含過去盈利增長(以及進一步的增長預測)的有趣公司。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論